Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 90

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 19
Chunk 90
---
 relation to the transaction the remaining transaction
costs have been charged to retained earnings.

On 4 October 2024 the Company effected
a ratio change in the number of Ordinary Shares represented by ADSs from 400 Ordinary Shares per ADS to 10,000 Ordinary Shares per ADS.

During the year the Company issued the
following warrants over ADSs, and these were recognised in the warrant reserve until exercise:

  Schedule of warrant reserve recognize                               
  Exercise price                                0.0025      £ Nil     
  As at 1 January 2024                         167,446      –         
  Issued:                                                             
  May 2024 Warrant inducement                        –      37,260    
  July 2024 Registered Direct Offering          11,157      –         
  Exercised                                  ( 161,161      ( 37,260  
  Lapsed                                          ( 27      –         
  As at 31 December 2024                        17,415      –         

Numbers of warrants and related exercise
prices are after the impact of the ADS ratio changes on 4 October 2024.

In accordance with the Articles of Association
for the Company adopted on 22 November 2024, the share capital of the Company consists of an unlimited number of ordinary shares of nominal
value £0.00005 each. Ordinary and deferred shares were recorded as equity.

Rights attaching to the shares
following the incorporation of Biodexa Pharmaceuticals plc

Shares classified as equity

The holders of ordinary shares in the
capital of the Company have the following rights:

(a) to receive notice of, to attend
and to vote at all general meetings of the Company, in which case shareholders shall have one vote for each share of which he is the holder;
and,

(b) to receive such dividend as
is declared by the Board on each share held.

The holders of both classes of deferred
shares in the capital of the Company:

(a) shall not be entitled to receive
notice of or to attend or speak at any general meeting of the Company or to vote on any resolution to be proposed at any general meeting
of the Company; and

(b) shall not be entitled to receive
any dividend or other distribution of out of the profits of the Company.

In the event of a distribution of assets,
the deferred shareholders shall receive the nominal amount paid up on such share after the holder of each ordinary share shall have received
(in cash or specie) the